ID cytarabine

DRUG2 trials

Sponsors

University Hospital, Angers, Fujian Medical University

Conditions

AML in RemissionAcute Myeloid Leukemia (AML)

Phase 2

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

RecruitingNCT02416388

University Hospital, AngersAcute Myeloid Leukemia (AML)

Start: 2015-01-31End: 2032-01-31Target: 3100Updated: 2024-08-07

Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

Fujian Medical UniversityAML in Remission

Start: 2020-01-31End: 2024-05-31Target: 320Updated: 2020-01-03

Related Papers

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Blood2025-11-03

Frequency and impact of FLT3-ITD microclones in younger AML patients

Blood2025-11-03

Intermediate-Dose Cytarabine as Postinduction AML Therapy

NEJM Evidence2025-06-244 citations

Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Blood2024-11-054 citations

Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood2024-11-05

Cyclosporine <i>Versus</i> Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood2024-11-05

Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML

Blood2023-11-021 citations